DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation today announced the discontinuation of its Phase 3 ICoN-1 clinical trial evaluating MNKD-101, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback